Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
Falini L, Venanzi A, Tini V, Innocente A, Ballanti S, Saldi S, Sivolella S, Pierini A, Aristei C, Tiacci E, Perriello VM, Falini B. Falini L, et al. Among authors: ballanti s. Haematologica. 2023 Jan 1;108(1):290-294. doi: 10.3324/haematol.2022.281351. Haematologica. 2023. PMID: 35899391 Free PMC article. No abstract available.
Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax.
Perriello VM, Falini L, Ruggeri L, Sorcini D, Ballanti S, Flenghi L, Baffa N, Covarelli P, Sportoletti P, Pierini A, Falini B. Perriello VM, et al. Among authors: ballanti s. EJHaem. 2023 Apr 10;4(2):559-562. doi: 10.1002/jha2.655. eCollection 2023 May. EJHaem. 2023. PMID: 37206291 Free PMC article. No abstract available.
Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement.
Saldi S, Perriello VM, Falini L, Ruggeri L, Fulcheri C, Ciardelli S, Innocente A, Ballanti S, Baffa N, Flenghi L, Pierini A, Aristei C, Falini B. Saldi S, et al. Among authors: ballanti s. Front Immunol. 2022 Jul 14;13:934700. doi: 10.3389/fimmu.2022.934700. eCollection 2022. Front Immunol. 2022. PMID: 35911683 Free PMC article.
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.
Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, Delia M, Ballanti S, Marchesi F, Mancini V, Orciuolo E, Cesaro S, Prezioso L, Fanci R, Nadali G, Chierichini A, Facchini L, Picardi M, Malagola M, Orlando V, Trecarichi EM, Tumbarello M, Aversa F, Rossi G, Pagano L; SEIFEM Group. Cattaneo C, et al. Among authors: ballanti s. Ann Hematol. 2018 Sep;97(9):1717-1726. doi: 10.1007/s00277-018-3341-6. Epub 2018 Apr 28. Ann Hematol. 2018. PMID: 29705860
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: ballanti s. Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35608183 Free article.
57 results